Linnaeus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.linnaeustx.com
A Trial of LNS8801 with or Without Pembrolizumab in Patients with Refractory Melanoma
Phase 2
Not yet recruiting
- Conditions
- Melanoma (Skin Cancer)Melanoma Stage IIIB-IVCutaneous MelanomaUnresectable Melanoma
- Interventions
- Drug: Chemotherapy (dacarbazine or temozolomide)Biological: Immunotherapy (Pembrolizumab)Biological: Immunotherapy (nivolumab and relatlimab)Biological: Immunotherapy (ipilimumab and nivolumab)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Linnaeus Therapeutics, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06624644
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Linnaeus Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04130516
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath